Drug Trial Radar · NCT04025957
A Study of SHR-1501 in Patients With Advanced Tumors
Last checked: Nov 19, 2026Latest source record: Sep 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Oct 30, 2019
Primary completion
Jul 31, 2022
Study completion Jul 31, 2022
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 19, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and tolerability of SHR-1501 in patients with advanced malignancies .
Conditions
- Advanced Malignancies
Interventions
SHR-1501Drug
Administered subcutaneously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicityTime frame: Approximately 2 years
- Maximum tolerated doseTime frame: Approximately 2 years
- Adverse event/Serious adverse eventTime frame: Approximately 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer hospital, Chinese academy of medical sciences
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.